SK10762003A3 - Farmaceutický prostriedok obsahujúci parazolo-[4,3-d]pyrimidíny a nitráty alebo tienopyrimidíny a nitráty - Google Patents

Farmaceutický prostriedok obsahujúci parazolo-[4,3-d]pyrimidíny a nitráty alebo tienopyrimidíny a nitráty Download PDF

Info

Publication number
SK10762003A3
SK10762003A3 SK1076-2003A SK10762003A SK10762003A3 SK 10762003 A3 SK10762003 A3 SK 10762003A3 SK 10762003 A SK10762003 A SK 10762003A SK 10762003 A3 SK10762003 A3 SK 10762003A3
Authority
SK
Slovakia
Prior art keywords
pyrimidin
chloro
methyl
pharmaceutical composition
methoxybenzylamino
Prior art date
Application number
SK1076-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Hans-Michael Eggenweiler
Volker Eiermann
Pierre Schelling
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001104097 external-priority patent/DE10104097A1/de
Priority claimed from DE2001104095 external-priority patent/DE10104095A1/de
Priority claimed from DE2001104096 external-priority patent/DE10104096A1/de
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SK10762003A3 publication Critical patent/SK10762003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SK1076-2003A 2001-01-31 2001-12-27 Farmaceutický prostriedok obsahujúci parazolo-[4,3-d]pyrimidíny a nitráty alebo tienopyrimidíny a nitráty SK10762003A3 (sk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE2001104097 DE10104097A1 (de) 2001-01-31 2001-01-31 Pharmazeutische Formulierung enthaltend Thienopyrimidine und Nitrate
DE2001104095 DE10104095A1 (de) 2001-01-31 2001-01-31 Pharmazeutische Formulierung enthaltend Pyrazolo [4,3-d]pyrimidine und Nitrate
DE2001104096 DE10104096A1 (de) 2001-01-31 2001-01-31 Pharmazeutische Formulierung enthaltend Thienopyrimidine und Nitrate
PCT/EP2001/015324 WO2002060449A2 (de) 2001-01-31 2001-12-27 Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und nitrate oder thienopyrimidine und nitrate

Publications (1)

Publication Number Publication Date
SK10762003A3 true SK10762003A3 (sk) 2004-01-08

Family

ID=27214255

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1076-2003A SK10762003A3 (sk) 2001-01-31 2001-12-27 Farmaceutický prostriedok obsahujúci parazolo-[4,3-d]pyrimidíny a nitráty alebo tienopyrimidíny a nitráty

Country Status (14)

Country Link
US (1) US20040077664A1 (cs)
EP (1) EP1355649A2 (cs)
JP (1) JP2004517940A (cs)
KR (1) KR20030070149A (cs)
CN (1) CN1499969A (cs)
AR (1) AR035741A1 (cs)
BR (1) BR0116849A (cs)
CA (1) CA2436209A1 (cs)
CZ (1) CZ20032339A3 (cs)
HU (1) HUP0302987A2 (cs)
MX (1) MXPA03006717A (cs)
PL (1) PL362408A1 (cs)
SK (1) SK10762003A3 (cs)
WO (1) WO2002060449A2 (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
CA2562251C (en) * 2004-04-07 2009-04-28 Pfizer Inc. Pyrazolo'4,3-d pyrimidines
JPWO2006126718A1 (ja) * 2005-05-27 2008-12-25 田辺三菱製薬株式会社 ピラゾロピリミジン誘導体
EP1941876A1 (en) * 2006-12-28 2008-07-09 Lacer, S.A. Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension
EP2595993B1 (en) 2010-07-23 2018-04-18 President and Fellows of Harvard College Tricyclic proteasome activity enhancing compounds
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
EP2806875B1 (en) 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
SE542968C2 (en) 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
DE19752952A1 (de) * 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine
DE19819023A1 (de) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine

Also Published As

Publication number Publication date
WO2002060449A3 (de) 2003-01-30
KR20030070149A (ko) 2003-08-27
CA2436209A1 (en) 2002-08-08
PL362408A1 (en) 2004-11-02
CN1499969A (zh) 2004-05-26
BR0116849A (pt) 2004-02-25
HUP0302987A2 (hu) 2003-12-29
WO2002060449A2 (de) 2002-08-08
AR035741A1 (es) 2004-07-07
JP2004517940A (ja) 2004-06-17
EP1355649A2 (de) 2003-10-29
MXPA03006717A (es) 2003-10-24
US20040077664A1 (en) 2004-04-22
CZ20032339A3 (cs) 2004-09-15

Similar Documents

Publication Publication Date Title
US6420368B1 (en) Thienopyrimidines
US20040034040A1 (en) Use of thienopyrimidines
AU773878B2 (en) Pyrazolo(4,3-d)pyrimidines
SK18222001A3 (sk) Derivát tienopyrimidínu ako inhibítor fosfodiesterázy, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
SK15972000A3 (sk) Derivát kondenzovaného tienopyrimidínu s pde v inhibičným pôsobením, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
SK10762003A3 (sk) Farmaceutický prostriedok obsahujúci parazolo-[4,3-d]pyrimidíny a nitráty alebo tienopyrimidíny a nitráty
SK10782003A3 (sk) Farmaceutický prostriedok obsahujúci parazolo [4,3-d]pyrimidíny a endotelínové receptorové antagonisty alebo tienopyrimidíny a endotelínové receptorové antagonisty
US20040023990A1 (en) Use of pyrazolo[4,3-d]pyrimidines
US20040023991A1 (en) Use of pyrazolo[4,3-d]pyrimidines
JP4927299B2 (ja) チエノピリミジン
KR20020026011A (ko) 티에노피리미딘의 용도